Trials / Completed
CompletedNCT06016556
A Study of COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir in the Kingdom of Saudi Arabia
A Retrospective Observational Non-Interventional Study (NIS) to Assess Patient Characteristics and Healthcare Resource Use (HCRU) Among COVID-19 Patients Receiving Treatment With Nirmatrelvir; Ritonavir (PAXLOVID TM) in the Kingdom of Saudi Arabia (KSA).
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 250 (actual)
- Sponsor
- Pfizer · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The aim of this study is to describe the baseline demographic, clinical characteristics, and Healthcare Resource Use (HCRU) of adult (≥18 years) COVID-19 patients who have been prescribed nirmatrelvir, ritonavir treatment.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | nirmatrelvir, ritonavir | single cohort |
Timeline
- Start date
- 2023-10-17
- Primary completion
- 2024-04-09
- Completion
- 2024-04-09
- First posted
- 2023-08-29
- Last updated
- 2025-06-05
- Results posted
- 2025-04-29
Locations
3 sites across 1 country: Saudi Arabia
Source: ClinicalTrials.gov record NCT06016556. Inclusion in this directory is not an endorsement.